Publications by authors named "B Yamout"
Background: CLASSIC-MS explored long-term outcomes of patients treated with cladribine tablets.
Objective: Assess long-term efficacy in patients previously enrolled in ORACLE-MS, a Phase III parent trial.
Methods: ORACLE-MS included patients with a first clinical demyelinating event (FCDE or clinically isolated syndrome) who received ⩾1 course of cladribine tablets or placebo.
The differential diagnosis of multiple sclerosis can present specific challenges in patients from Latin America, Africa, the Middle East, eastern Europe, southeast Asia, and the Western Pacific. In these areas, environmental factors, genetic background, and access to medical care can differ substantially from those in North America and western Europe, where multiple sclerosis is most common. Furthermore, multiple sclerosis diagnostic criteria have been developed primarily using data from North America and western Europe.
View Article and Find Full Text PDFArticle Synopsis
- - The study examines the effectiveness of high-efficacy disease-modifying treatments (hDMTs) versus low-efficacy treatments (lDMTs) in reducing spinal cord lesions in multiple sclerosis (MS) patients, noting the limited previous data on this specific outcome.
- - Researchers analyzed data from patients with relapse-onset MS who underwent MRI scans before and after starting treatment, comparing new lesions in both cord and brain areas.
- - Results indicate that while hDMTs significantly reduced new brain lesions and MS relapses compared to lDMTs, they did not show a significant benefit in preventing new spinal cord lesions.
Background: Neuromyelitis optica spectrum disorder (NMOSD) can be categorised into aquaporin-4 antibody (AQP4-IgG) NMOSD or seronegative NMOSD. While our knowledge of AQP4-IgG NMOSD has evolved significantly in the past decade, seronegative NMOSD remains less understood. This study aimed to evaluate the predictors of relapses and treatment responses in AQP4-IgG NMOSD and seronegative NMOSD.
View Article and Find Full Text PDFBackground: There is a lack information regarding risk factors associated with worse COVID-19 outcomes in patients with multiple sclerosis (MS) in the MENA region.
Methods: This is a multicenter, retrospective cohort study that included all MS patients with a suspected or confirmed COVID-19 infection using the MENACTRIMS registry. The association of demographics, disease characteristics, and use of disease-modifying therapies (DMTs) with outcomes and severity of COVID-19 were evaluated by multivariate logistic model.